An analysis of the relationship between breast cancer resistance protein BCRP and breast cancer
![Image](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi9T8Tly6FfNOK4q75DRa4O2Tgz1pmRVRP1pUso08wRDvpeCWAbb0QIXh3tiPFsU1-vfvPE3vv4eyk-U9a7A_gEf03g-SfzXG6wpooARQtl9PWIH_25y4hgHSUlr4dOJkE-qs3ay5F97uDLxfQym34Ff362bGokMUQDh1D2zLArMcucSAbRzLogdNstwg/w640-h360/drug-metabolism.jpg)
Breast cancer is a common malignancy in women, and multidrug resistance is one of the main reasons affecting the efficacy of chemotherapy and patient survival in breast cancer. A tumor drug resistance-associated protein, BCRP, has been reported in breast cancer drug-resistant cell lines. Also, BCRP is a transporter, mainly responsible for the excretion of endogenous and exogenous substances outside the cell, and has a vital role in drug metabolism research. The BCRP gene of human breast cancer resistance protein (BCRP) is located in the chromosome 4q22 region. It encodes 655 amino acids, which are present in several vital organs in the body, such as the small intestine, placenta, liver, and kidney. It is essential for drug absorption, distribution, metabolism, and excretion. Drug transport proteins play a vital role in drug metabolism kinetics. According to the drug transport mode, drug transport proteins can be divided into drug uptake proteins and drug efflux proteins. As a membe